ENDRA Life Sciences- Warrants (12/05/2022) Overview
Get informed when a big investor buys or sells
+ Follow-0.75
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
ENDRA Life Sciences- Warrants (12/05/2022) (NDRAW) currently reports a P/E ratio of -0.75. That is below the Technology sector average of 39.36. Use the charts on this page to explore ENDRA Life Sciences- Warrants (12/05/2022)'s P/E ratio history and peer comparisons.
ENDRA Life Sciences- Warrants (12/05/2022)'s P/E ratio of -0.75 is lower than the Technology sector average of 39.36. That is roughly 101.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates ENDRA Life Sciences- Warrants (12/05/2022)'s market price to a fundamental measure such as earnings, sales, or book value. At -0.75, NDRAW can look expensive or cheap only in context — versus its own history, growth rate, and Technology peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.75, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 39.36. From there, open related valuation or income-statement pages for ENDRA Life Sciences- Warrants (12/05/2022), and consider following NDRAW for alerts when major investors trade the stock.
ENDRA Life Sciences- Warrants (12/05/2022) is classified in the Technology sector. On P/E ratio, it currently shows -0.75 versus a sector average near 39.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing NDRAW with unrelated industries.
